Loading...
Loading...
Generating destination analysis
Unlock Full NNOX Analysis
UpgradeMarket Cap
$800M
P/E
N/A
Revenue Growth
+120.0%
Gross Margin
N/A
ROE
N/A
As a small-cap healthcare company trading on the NASDAQ, Nano-X Imaging has established itself, with direct, concentrated exposure to the biotech and genomics theme. Disruptive medical imaging company with novel cold-cathode X-ray technology at fraction of cost. With a $0.8B market capitalization and no current profitability, the company demonstrates exceptional revenue growth at +120% year-over-year.
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
ARK Genomic Revolution ETF
ETF focused on companies advancing genomics, gene editing, and therapeutics.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.